Th	T helper
TNF	tumour necrosis factor
IFN-γ	interferon gamma
IL	interleukin
BMI	body mass index
HDL-cholesterol	high-density lipoprotein-cholesterol
BFM	body fat mass
FFM	fat-free mass
SMM	skeletal muscle mass
TBW	total body water
ICW	intracellular water
ECW	extracellular water
BCM	body cell mass
FFMI	fat-free mass index
BFMI	body fat mass index
SMMI	skeletal muscle mass index
BIA	bioelectrical impedance analyzer
PA	phase angle
LDL-cholesterol	low-density lipoprotein-cholesterol
ALT	alanine aminotransferase
AST	aspartate aminotransferase
GGT	gamma glutamyl transferase
CRP	c-reactive protein
ESR	erythrocyte sedimentation rate
PASI	psoriasis area severity index
DLQI	dermatology life-quality index
HbA1c%	haemoglobin A1c%
BFP	body fat percent
IQR	interquartile ranges
MTX	methotrexate
FTO gene rs9939609	alpha-ketoglutarate-dependent dioxygenase gene rs9939609 variant
NAFLD	non-alcholic fatty liver disease
IL-17R	interleukin-17 receptor
LPS	lipopolysaccharide
CCL	CC chemokine ligand
mAb	monoclonal antibody
VOYAGE 1 study	A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis
VOYAGE 2 study	A study of guselkumab in the treatment of participants with moderate to severe plaque-type psoriasis with randomized withdrawal and retreatment
UltIMMA-1 study	BI 655066 (risankizumab) compared to placebo and active comparator (ustekinumab) in patients with moderate to severe chronic plaque psoriasis
UltIMMA-2 study	BI 655066 versus placebo and active comparator (ustekinumab) in patients with moderate to severe chronic plaque psoriasis
FIXTURE	Safety and efficacy of secukinumab compared to etanercept in subjects With moderate to severe, chronic, plaque-type psoriasis
ERASURE	Efficacy and safety of subcutaneous secukinumab for moderate to severe chronic plaque-type psoriasis for up to 1 year
SCULPTURE	Efficacy and safety of subcutaneous secukinumab (AIN457) for moderate to severe chronic plaque-type psoriasis assessing different doses and dose regimens
hs-CRP	high-sensitivity c-reactive protein
UNCOVER-1,2	A phase 3 study in participants with moderate to severe psoriasis
UNCOVER-3	A study in participants with moderate to severe psoriasis
NF-kB	nuclear factor kappa light chain enhancer of activated B cells
BSA	body surface area
WHO	World Health Organisation